Rapport Therapeutics
RAPP | NASDAQ
$24.82
-$1.33 (-5.09%)
At close: Nov 16, 2026, 4:00 PM ET
$24.39
-$0.43 (-1.73%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Rapport Therapeutics Company Profile
Company profile explainedCompany Profile
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Abraham N. Ceesay | Chief Executive Officer, President, Treasurer & Director |
| Cheryl Gault | Chief Operating Officer |
| Karina Chmielewski | Chief Information Officer & Head of Operations |
| Kathleen A. Wilkinson | Chief People Officer |
| Troy A. Ignelzi | Chief Financial Officer |
| Brian Corcoran | Controller |
| Craig Wilhelmson | Head of Data Management |
| David Bredt | Founder & Chief Scientific Officer |
| Gregg Keaney | Senior Vice President of CMC & Product Development |
| Jeffrey Sevigny | Chief Medical Officer |
| Julie DiCarlo | Head of Communications & Investor Relations |
| Steven Paul | Founder & Independent Chairman |
| Swamy Yeleswaram | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 30, 2026 | 8-K | Current Report |
| Oct 30, 2026 | 424B5 | Filing |
| Oct 30, 2026 | 424B5 | Filing |
| Oct 29, 2026 | 305B2 | Filing |
| Oct 28, 2026 | FWP | Filing |
| Oct 28, 2026 | FWP | Filing |
| Oct 28, 2026 | FWP | Filing |
| Oct 28, 2026 | FWP | Filing |
| Oct 27, 2026 | 424B5 | Filing |
Rapport Therapeutics
| Country | United States |
| IPO Date | Jun 7, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Abraham N. Ceesay |
Contact Details
99 High Street Boston,
Massachusetts 02110 United States
Stock Details
| Ticker Symbol | RAPP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002012593 |
| CUSIP Number | 75383L102 |
| ISIN Number | US75383L1026 |
| SIC Code | 2834 |
Recent News
- 13 days ago / globenewswire.comRapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
- 14 days ago / globenewswire.comRapport Therapeutics to Participate in Upcoming Investor Conferences
- 15 days ago / globenewswire.comRapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
- 20 days ago / globenewswire.comRapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
- 20 days ago / globenewswire.comRapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
- 23 days ago / marketbeat.comRapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
- 27 days ago / seekingalpha.comRapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
- 28 days ago / benzinga.comWhy Is Rapport Therapeutics Stock Trading Higher Today?
- 28 days ago / barrons.comInside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
- 28 days ago / globenewswire.comRapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Add to Watchlist
Select watchlists to add or remove RAPP